Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
Conditions
Interventions
Vemurafenib
Locations
280
Albania
University "Mother Theresa" Hospital Center; Oncology Department
Tirana, Albania
Hospital Britanico; Oncologia
Buenos Aires, Argentina
Fundación CIDEA
Buenos Aires, Argentina
Inst. Alexander Fleming; Oncologia
Buenos Aires, Argentina
Melanoma Institute Australia
North Sydney, New South Wales, Australia
Newcastle Mater Misericordiae Hospital; Oncology
Waratah, New South Wales, Australia
Start Date
March 1, 2011
Primary Completion Date
February 24, 2016
Completion Date
February 24, 2016
Last Updated
December 18, 2017
NCT07371663
NCT06794775
NCT01898039
NCT06209580
NCT05478876
NCT04879654
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions